髓母细胞瘤患者来源原位异种移植模型缺乏功能性血脑屏障
研究采用动态增强MRI评估多种髓母细胞瘤小鼠模型的血脑肿瘤屏障通透性,发现所有移植模型均出现对比增强,而基因工程小鼠模型(GEMM)无增强,提示移植模型血脑肿瘤屏障完整性异常,对临床前治疗评估有重要影响。
要点
- 髓母细胞瘤移植模型血脑肿瘤屏障通透性增加,GEMM模型则无。
- 不同临床前模型的血脑肿瘤屏障完整性和肿瘤血管表型存在功能差异。
- 选择临床前模型评估髓母细胞瘤新药时需考虑血脑屏障完整性。
核心结论
- 常用髓母细胞瘤临床前模型间血脑肿瘤屏障完整性和肿瘤血管表型存在功能差异,对新型治疗药物的临床前评估有重要影响。
研究设计与样本
- 研究采用动态增强磁共振成像评估Sonic Hedgehog型髓母细胞瘤GEMM、患者来源原位异种移植模型(SHH和Gp3)及GEMM肿瘤细胞原位移植模型的血脑肿瘤屏障通透性,并用免疫荧光分析肿瘤相关血管结构和亚细胞特征。
主要发现
- 所有髓母细胞瘤移植模型均观察到对比增强。
- GEMM虽肿瘤负荷显著但未观察到对比增强。
- 所有移植模型的血脑肿瘤屏障完整性细胞分析均显示异常,与MRI观察到的通透性水平相关。
临床怎么用
- 在髓母细胞瘤新药临床前评估中,应考虑所用模型的血脑肿瘤屏障完整性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel targeted therapies for children diagnosed with medulloblastoma (MB), the most common malignant pediatric brain tumor, are urgently required. A major hurdle in the development of effective therapies is the impaired delivery of systemic therapies to tumor cells due to a specialized endothelial blood-brain barrier (BBB). Accordingly, the integrity of the BBB is an essential consideration in any preclinical model used for assessing novel therapeutics. This study sought to assess the functional integrity of the BBB in several preclinical mouse models of MB. METHODS: Dynamic contrast enhancement magnetic resonance imaging (MRI) was used to evaluate blood-brain-tumor barrier (BBTB) permeability in a murine genetically engineered mouse model (GEMM) of Sonic Hedgehog (SHH) MB, patient-derived orthotopic xenograft models of MB (SHH and Gp3), and orthotopic transplantation of GEMM tumor cells, enabling a comparison of the direct effects of transplantation on the integrity of the BBTB. Immunofluorescence analysis was performed to compare the structural and subcellular features of tumor-associated vasculature in all models. RESULTS: Contrast enhancement was observed in all transplantation models of MB. No contrast enhancement was observed in the GEMM despite significant tumor burden. Cellular analysis of BBTB integrity revealed aberrancies in all transplantation models, correlating to the varying levels of BBTB permeability observed by MRI in these models. CONCLUSIONS: These results highlight functional differences in the integrity of the BBTB and tumor vessel phenotype between commonly utilized preclinical models of MB, with important implications for the preclinical evaluation of novel therapeutic agents for MB.
引用
- Genovesi LA, Puttick S, Millar A, et al. Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier. Neuro Oncol. 2021. PMID: 33258962. doi:10.1093/neuonc/noaa266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。